Jason Zemansky

Peter Lawson

George Farmer

Justin Zelin

Michael Schmidt

Salim Syed

Yigal Nochomovitz

Anupam Rama

Bradley Canino

Chris Shibutani

Kalpit Patel

Kelly Shi

Priyanka Grover

Xiaochuan Dai

Ashiq Mubarack

Chloe

David Dai

Dingding Shi

Ellen Horste

Jeet Mukherjee

Kevin Strang

Mayank Mamtani

Philip Nadeau

Phil Nadeau

- Syndax Pharmaceuticals is experiencing strong launches for its two approved medicines, **Revuforj** and **Ictimo**. Revuforj showed **43% net sales growth** from Q1 to Q2 2025, generating over **$50 million** since launch and treating over **500 patients** through June.  **[1395937_tx_379728_1]**  Ictimo has generated almost **$50 million** between its first partial and first full quarter, with **700 patients** treated through June.  **[1395937_tx_379728_7]** 
- The company anticipates a significant market expansion for **Revuforj** with an **FDA PDUFA date of October 25th, 2025**, for the **NPM1-mutated AML** indication, which represents a larger market of approximately **4,500 patients** compared to KMT2A's **2,000 patients**.  **[1395937_tx_379728_3]** 
- Syndax projects the total market opportunity for Revuforj, including frontline treatment, to be **$5 billion**, affecting roughly **9,000 patients**.  **[1395937_tx_379728_5]** 
- Financially, Syndax is funded to profitability, having raised **$350 million** through a royalty monetization, and expects to keep operating expenses **flat to 2025 levels** for the next two to three years.  **[1395937_tx_379728_9]**  Ictimo is already profitable on a contribution profit basis, reporting over **$9 million** in collaboration revenue in its first full quarter.  **[1395937_tx_379728_9]**

Syndax Pharmaceuticals Discusses Commercial Performance and Upcoming Milestones

Syndax Pharmaceuticals (SNDX)